The impact of age on antidepressant response: A mega-analysis of individuals with major depressive disorder

Mills, Jeffrey A.; Suresh, Vikram; Mayes, Taryn L.; Gentry, Melanie T.; Trivedi, Madhukar H.; Croarkin, Paul E.

doi:10.1016/j.jpsychires.2023.01.043

Cited by 17 publications

(6 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This possibility is supported in the context of nonpsychedelic pharmacotherapies. Specifically, a meta-analysis of individuals with major depressive disorder revealed that older patients (>55 years old) exhibited slower and decreased responses to pharmacotherapy compared to younger adults aged 21–35 (Strawn et al, 2023). This age-related difference in treatment response could also be explained by older adults’ greater systemic inflammation, molecular senescence, more chronicity, or unique psychosocial stressors (Strawn et al, 2023).…”

Section: Discussionmentioning

confidence: 99%

“…Specifically, a meta-analysis of individuals with major depressive disorder revealed that older patients (>55 years old) exhibited slower and decreased responses to pharmacotherapy compared to younger adults aged 21–35 (Strawn et al, 2023). This age-related difference in treatment response could also be explained by older adults’ greater systemic inflammation, molecular senescence, more chronicity, or unique psychosocial stressors (Strawn et al, 2023). However, it is important to acknowledge the complexities of age-related psychedelic effects in the SOFV population experiencing ongoing functional impairment, especially considering the individual variations among different age groups.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Predictors of psychedelic treatment outcomes among special operations forces veterans.

Xin,

Armstrong,

Averill

et al. 2023

Psychology of Consciousness: Theory, Research, and Practice

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Predictors of psychedelic treatment outcomes among special operations forces veterans.

Xin,

Armstrong,

Averill

et al. 2023

Psychology of Consciousness: Theory, Research, and Practice

View full text Add to dashboard Cite

“…Age differences further complicate the landscape of antidepressant use and response. A megaanalysis of individuals with major depressive disorder (MDD) revealed that patients aged 21 years and younger, as well as those older than 55 years, exhibited slower and less robust responses to pharmacotherapy compared to those aged 21 to 35 years [13]. Additionally, data from the National Health and Nutrition Examination Survey (NHANES) indicated that antidepressant use increases with age, from 3.4% among individuals aged 12-19 to 19.1% among those aged 60 and over [1].…”

Section: Demographic Differences In Antidepressant Usementioning

confidence: 99%

Exploring the Digital Landscape of Antidepressant Use: Demographic Insights, Emotional Analysis, and Topic Modeling (Preprint)

Zhu,

Zhang,

Jin

et al. 2024

Preprint

View full text Add to dashboard Cite

BACKGROUND Antidepressant medications are widely used to manage depression and anxiety disorders. Given that these medications have been around for many years, their side effects are well documented. Apart from common side effects, there are new emerging data reporting unexpected side effects or stress related challenges that clinicians should be aware of. OBJECTIVE The goal of this study to analyze the demographic profiles, symptomatology, and platform-specific differences in online discussions about antidepressant side effects. Exploring the antidepressant side effects in different gender and age, then the clinical with detailed information to improve the documentation and management of drug side effects. METHODS We collected dataset from Ask a patient and Reddit platform. A mixed methods approach including quantitative analysis and qualitative analysis. Which we leverage Natural Language Processing method to examine the demographic and symptoms comments, and exploring the language linguistic patterns on word, topic, and theme of posts. RESULTS The analysis highlighted significant gender-based differences in antidepressant side effects. Females reported more gastrointestinal, neurological, sleep, general physical, and emotional symptoms, while males reported more sexual health issues. Users frequently discussed withdrawal symptoms and challenges with switching medications, revealing anxiety about the withdrawal process. Unique symptoms such as toe infections, visual changes, and pulsatile tinnitus were also noted. The strong correlation between fear and neurological, gastrointestinal, and sleep-related symptoms suggests these physical symptoms significantly contribute to emotional distress. CONCLUSIONS These findings underscore the necessity for gender-sensitive healthcare approaches and highlight new concerns that are not typically covered in standard drug descriptions. Addressing these issues directly in consultations can improve patient outcomes by fostering better adherence to medication regimens and enhancing overall treatment satisfaction. Future research should focus on understanding the unique challenges faced by specific demographics, particularly women in reproductive age who use birth control, to provide more effective and personalized care.

show abstract

“…Po pierwsze, jak wykazano w metaanalizie Strawna i wsp. [28], odpowiedź na leczenie przeciwdepresyjne różni się w zależności od wieku pacjentów, przy czym jest wyższa u osób w wieku 22-35 lat w porównaniu z osobami w wieku 36-54 lat. Po drugie, dłuższy czas trwania leczenia depresji może ograniczać skuteczność LPD [29].…”

Section: Dyskusjaunclassified

TED (Trazodone Effectiveness in Depression): effectiveness of trazodone extended-release in subjects with unsatisfactory response to SSRIs

Siwek,

Chrobak,

Krupa

et al. 2023

Psychiatr Pol

View full text Add to dashboard Cite

Cel pracyInhibitory wychwytu serotoniny (SSRI) są najczęściej stosowanymi lekami w leczeniu epizodów dużej depresji (major depressive disorder- MDD). Niemniej jednak, około 50% pacjentów z MDD nie osiąga odpowiedzi terapeutycznej w wyniku leczenia SSRI i istnieje niewiele danych dotyczących tego, które leki są skuteczne jako leczenie drugiego rzutu u pacjentów, którzy nie odpowiadają na leczenie SSRI. W niniejszej pracy przeanalizowano dane 79 pacjentów z MDD, aby ocenić efektywność trazodonu XR w grupach pacjentów leczonych de novo oraz tych, u których zmieniono lek na trazodon XR po nieudanej próbie leczenia SSRI.MetodaPomiary przeprowadzono na początkowym etapie oraz w 2., 4., 8. i 12. tygodniu za pomocą narzędzi do oceny nasilenia: depresji (Skala Depresji Montgomery-Åsberg, Krótki Inwentarz Symptomatologii Depresji wypełniany przez pacjenta i klinicystę - główne punkty końcowe badania), efektywności terapeutycznej (Skala Ogólnego Wrażenia Klinicznego), anhedonii (Skala Przyjemności Snaith-Hamilton), lęku (Skala Lęku Hamiltona), bezsenności (Ateńska Skala Bezsenności), funkcjonowania psychospołecznego (Skala Niepełnosprawności Sheehana) i funkcjonowania seksualnego (Kwestionariusz Funkcji Seksualnych u Kobiet / Międzynarodowy Indeks Funkcji Erekcji u mężczyzn). Poziomy odpowiedzi na leczenie i remisji były w dużej mierze podobne w obu badanych grupach.WynikiWyniki wskazały, że efektywność trazodonu XR w leczeniu pacjentów z MDD, którzy nie reagowali na SSRI podawane jako leczenie pierwszego rzutu w danym epizodzie depresyjnym, była porównywalna do tej obserwowanej u pacjentów leczonych de novo. Ponadto, trazodon XR efektywnie redukował nasilenie depresji, lęku, bezsenności, anhedonię i poprawiał funkcjonowanie psychospołeczne (w obu grupach).WnioskiDodatkowo, trazodon XR jako leczenie drugiego rzutu poprawiał funkcje seksualne u mężczyzn, którzy wcześniej byli leczeni SSRI.

show abstract

The impact of age on antidepressant response: A mega-analysis of individuals with major depressive disorder

Cited by 17 publications

References 39 publications

Predictors of psychedelic treatment outcomes among special operations forces veterans.

Predictors of psychedelic treatment outcomes among special operations forces veterans.

Exploring the Digital Landscape of Antidepressant Use: Demographic Insights, Emotional Analysis, and Topic Modeling (Preprint)

TED (Trazodone Effectiveness in Depression): effectiveness of trazodone extended-release in subjects with unsatisfactory response to SSRIs

Contact Info

Product

Resources

About